{
  "docId": "019de072-7781-7512-96cc-a2b05ce755c7",
  "docSlug": "b1746432eb5f270eac90273cddb862aa",
  "documentTitle": "Bionomics | Investor Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 38,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a structured table layout to define the clinical trial parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7781-7512-96cc-a2b05ce755c7/32",
  "deckHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7",
  "deckJsonHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7.json",
  "deckAnchorHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.25,
        "x": 0.02,
        "y": 0.12
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c428bf39-9f1a-4415-a0ce-48051ef90727",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.65,
        "x": 0.28,
        "y": 0.0012
      },
      "kind": "table",
      "text": "Study Design: Multi-center, randomized, double-blind, placebo-controlled; BNC210 150 mg, 300 mg, 600 mg and placebo (1:1:1:1); 12-week treatment period; 193 participants; 20 US sites / 6 Australian sites. Key Selection Criteria: Current diagnosis of PTSD as defined by CAPS-5. Key Study Objectives: Assess effects on symptoms; assess safety and tolerability.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ec1d789-6a3b-4f88-a9b2-87f2d9895f67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 2 Trial of BNC210 in Adults with Post-Traumatic Stress Disorder (PTSD)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f162f9ba-ba64-425f-823e-b00b6e180889",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "ae7f4df9-bb04-47cd-b7bd-ac7389daf463",
      "evidence": "table/data: Study Design: Multi-center, randomized, double-blind, placebo-controlled; BNC210 150 mg, 300 mg, 600 mg and placebo (1:1:1:1); 12-week treatment period; 193 participants; 20 US sites / 6 Australian sites. Key",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "c64663e8-018a-4c0b-871d-c12b39de8b18",
      "evidence": "Structured presentation of study design, criteria, and objectives.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}